Gene Scale 2027
Scaling Gene Therapy for Prevalent Diseases
Dates: March 08-10, 2027
Location: Hyatt Regency La Jolla, San Diego, California
About Gene Scale 2027
Bridging Discovery and Industrial Scale in Gene Therapy
The "proof of concept" era of gene therapy is now behind us. As we move into 2027, the field stands at a pivotal turning point — shifting from treating rare ultra-orphan diseases to addressing large patient populations suffering from prevalent chronic conditions such as cardiovascular diseases, neurodegenerative disorders, and metabolic syndromes.
Gene Scale 2027 is the premier industry-academia alliance dedicated to solving the complex challenges of scaling gene therapies. This summit focuses on the “Last Mile” — moving from laboratory success to commercial, manufacturable, and reimbursable therapies capable of reaching millions of patients globally.
We bring together leading scientists, biotech executives, CMC experts, manufacturing leaders, regulatory authorities, and investors to tackle the biggest bottlenecks: advanced delivery systems, AI-driven manufacturing, modular production, regulatory harmonization, and innovative reimbursement models.
Apply to SpeakJoin 500+ pioneers in San Diego for Gene Scale 2027, the premier summit dedicated to scaling gene therapy for prevalent diseases. This is where leading scientists, biotech executives, manufacturers, and investors converge to solve the real challenges of delivery, manufacturing at scale, regulatory approval, and commercialization.
Gene Scale 2027 Speakers
Matthias Stephan
Professor, Translational Science and Therapeutics Division
Injectable bioinstructive microfoam for rapid bedside/in vivo
Why Attend Gene Scale 2027
The definitive summit for scaling gene therapy from rare diseases to prevalent chronic conditions.
Latest Clinical & Technical Advances
Access late-breaking data on precision editing, in-vivo delivery, non-viral vectors, and AI-optimized manufacturing.
High-Value Networking
Connect with 500+ key decision makers — biotech CEOs, VCs, CMC leaders, regulators, and manufacturing experts.
Focus on Industrial Scale
Move beyond proof-of-concept. Explore real solutions for commercialization, reimbursement, and treating large patient populations.
Agenda at a Glance
Precision 2.0 – Beyond the Double-Strand Break
Base and Prime Editing clinical readouts for Hypercholesterolemia and Amyloidosis. How "search-and-replace" technology has eliminated off-target fears.
In-Vivo Delivery: The End of the Hospital Stay
High-impact talks on LNP-mediated In-Vivo CAR-T. Can we treat 100,000 patients by eliminating ex-vivo engineering?
The Neuro-Genomic Frontier: Crossing the BBB
New capsid engineering and non-viral ligands for Alzheimer’s and Parkinson’s—moving from "managing symptoms" to "genetic reversal."
Epigenetic Silencing: The Permanent Switch
Utilizing CRISPR-off technology for chronic pain and hypertension without altering the DNA sequence.
Fast-Track Innovation: Late-Breaking Data Flash
Rapid-fire 10-minute presentations on the most recent 2027 clinical results, designed to attract venture-backed startups and PIs.
The AI-Driven Digital Twin
Using AI to simulate thousands of batch runs in seconds to optimize yield. Moving from "Trial and Error" to "Predictive Bioprocessing."
Modular Manufacturing: The Rise of the 'Bio-Pod'
A technical look at Decentralized Manufacturing. Deploying small-footprint, automated "pods" directly in regional hospitals.
Real-Time Release: The 24-Hour Quality Goal
Integrating Automated Analytical Development (ddPCR/NGS) into the production line to eliminate the 3-week QC wait time.
Non-Viral Vectors: Scaling the Supply Chain
Addressing the 2027 bottleneck: Scaling plasmid and LNP production for millions of doses vs. the scarcity of viral vectors.
The CDMO Round-Table: Automation vs. Labor
A high-level debate on the role of robotics in replacing manual cleanroom labour to ensure 2027 cost-viability.
The Pay-for-Performance Model: 2027 Data
A review of multi-year annuity payments for curative therapies. How payers are handling the shift to Heart Failure populations.
Global Regulatory Convergence: One Filing, Many Markets
How the FDA and EMA are harmonizing CMC requirements for prevalent disease trials to speed up 2027 launches.
Closing Panel: From Niche to Necessity
CEOs from top Biotechs discuss the 5-year roadmap for Cardiovascular Gene Therapy—the industry's next $100B market.
The 2030 Genomic Landscape
Investment trends for the "post-rare" era. Where will the smart money flow in 2027?
Interested in Sponsoring Gene Scale 2027?
If your company is interested in sponsoring Gene Scale 2027, we would be delighted to discuss the opportunities with you. Please send us a quick email, and we will promptly provide you with more information and our sponsorship brochure.
Sponsors
Gene Scale 2027: Advancing Innovation, Transforming Lives
Venue
Hyatt Regency La Jolla at Aventine
3777 La Jolla Village Dr, San Diego, CA 92122
United States
Contact
Address
259, Narendra Colony, Hyderabad, Telangana 502032
Call Us
+91 9059841607
Email Us
Our Newsletter
Subscribe to our newsletter and receive the latest news about our products and services!